Applications are now open for the Summer Venture Studio. Photo via rice.edu

Students at Rice University will have a new opportunity to have a taste of entrepreneurship this summer.

The Liu Idea Lab for Innovation and Entrepreneurship, or Lilie, has established a new startup accelerator program called the Summer Venture Studio. The program, which will run May 15 through August 7, is open to students of any major or year, including recent graduates.

“The Summer Venture Studio will empower student teams to accelerate their ventures and hit escape velocity,” says Kyle Judah, executive director of Lilie, in a news release. “We believe that with the right personalized program and resources, and led by our team of experienced founders, we can unlock students’ limitless potential to create the next generation of pillar companies for Houston, Texas and the world.”

The accepted students will work full-time with Lilie's one-on-one mentorship, programming, and up to $15,000 in equity-free funding per team — all provided in a dedicated coworking space.

“Summer Venture Studio offers Rice students the opportunity to work on their venture ideas with individualized programming customized to their experience, background and venture stage,” says Yael Hochberg, the Ralph S. O’Connor Professor in Entrepreneurship and head of the Rice Entrepreneurship Initiative. “The program is designed to blend seamlessly into students’ curricular and co-curricular experience throughout the academic year, ensuring that each student is met where they are in experience and entrepreneurial knowledge.”

The accelerator is looking for student teams of up to five members. The team lead must be a current student or have graduated within a month of the program's start. Applications are now open online and will be evaluated on a rolling basis.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.